TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06758531

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Instant coffee given as a drink
Description: Commercially available instant coffee (3.6 g) will be provided in the form of a drink prepared with 400 ml of water. A standard breakfast consisting of cereal with milk will be provided at 60 mins after the intervention. A standard lunch (cheese sandwiches, potato crisps and shortbread biscuits) will be given at 300 after coffee intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coffee given in a tablet form
Description: Commercially available instant coffee (3.6 g) will be provided as 4 tablets given with 400 ml of water. A standard breakfast consisting of cereal with milk will be provided at 60 mins after the intervention. A standard lunch (cheese sandwiches, potato crisps and shortbread biscuits) will be given at 300 after coffee intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control (placebo)
Description: A caffeine and coffee free control (3.6 g) will be provided as 4 tablets given with 400 ml of water. A standard breakfast consisting of cereal with milk will be provided at 60 mins after the intervention. A standard lunch (cheese sandwiches, potato crisps and shortbread biscuits) will be given at 300 after coffee intake.
Study: NCT06756464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROHKEA: Virtual Reality Therapy
Description: Using Interpretative Phenomenological Analysis (IPA): an exploration of the therapeutic benefits of a Virtual Reality enhanced Cognitive Behavioural Therapy (CBT) and movement (graded exposure) therapy 60-day chronic pain management programme (CPMP). Using the ROHKAE device and undertaking semi structures interviews, pain questionnaires and patient diaries to measure patient experience and pain management
Study: NCT05912699

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules contain microcrystalline cellulose only.
Study: NCT06757621

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Regional Nodal Irradiation
Description: Patients will receive chest wall / breast radiation with or without regional nodal irradiation
Study: NCT06758011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ivWatch
Description: Patients wear ivWatch device at time of already scheduled chemotherapy on study.
Study: NCT06757608

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of postprandial metabolism after intake of different meat
Description: 30 healthy adults (15 male and 15 female) consumed sardines (Opisthonema oglinum, marine fish), tambaqui (Colossoma macropomum, freshwater culture), and beef (Bos taurus). The meal consisted only of meat, with 7g per BMI unit. The postprandial response was observed for 5 hours, after an overnight fast.
Study: NCT05963724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-Time Computer Aided Detection
Description: This intervention involves using computer-aided detection using a real-time system (GI-Genius, Medtronic)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stanford Colonoscopy
Description: This involves white-light colonoscopy
Study: NCT06757608

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of postprandial metabolism after intake of different meat
Description: 30 healthy adults (15 male and 15 female) consumed sardines (Opisthonema oglinum, marine fish), tambaqui (Colossoma macropomum, freshwater culture), and beef (Bos taurus). The meal consisted only of meat, with 7g per BMI unit. The postprandial response was observed for 5 hours, after an overnight fast.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of postprandial metabolism after intake of different meat
Description: 30 healthy adults (15 male and 15 female) consumed sardines (Opisthonema oglinum, marine fish), tambaqui (Colossoma macropomum, freshwater culture), and beef (Bos taurus). The meal consisted only of meat, with 7g per BMI unit. The postprandial response was observed for 5 hours, after an overnight fast.
Study: NCT06091124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab 1200 mg IV on Day 1, once every 3 weeks for up to 4 cycles (each cycle = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 0.1g IV on Days 1-3, once every 3 weeks for up to 4 cycles (each cycle = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 35mg/m2 IV on Days 1-2, once every 3 weeks for up to 4 cycles (each cycle = 21 days)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Radical cystectomy should be performed within 4-6 weeks after completion of last dose
Study: NCT05579249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Description: Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine/Topiramate
Description: Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone/Bupropion
Description: Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
Study: NCT06352775

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: We will be using it in routes and doses consistent with its approved uses. Per the drug label information for Calcium Carbonate USP 500 mg found in the US National Library of Medicine, adults may take 2-4 tablets as symptoms occur and if pregnant to not exceed 10 tablets in 24 hours. Therefore, using a dosing of 500mg every 4 hours will be well below that guidance. When both cervical ripening has been completed and the oxytocin administration begins, the calcium carbonate treatment group will be given calcium carbonate 500mg every 4 hours (not to exceed 10 tablets in 24 hours) until they deliver.
Study: NCT05590923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OLA group: Olanzapine
Description: OLA group: olanzapine 10 mg oral each night on days 1-4 after HEC (or days 1-3 after MEC).~DEX group: dexamethasone (Decadron) 8 mg oral daily on days 2-4 after HEC (or days 2-3 after MEC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLA group: Olanzapine
Description: OLA group: olanzapine 10 mg oral each night on days 1-4 after HEC (or days 1-3 after MEC).~DEX group: dexamethasone (Decadron) 8 mg oral daily on days 2-4 after HEC (or days 2-3 after MEC).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DEX group: Dexamethasone
Description: DEX group: dexamethasone (Decadron) 8 mg oral daily on days 2-4 after HEC (or days 2-3 after MEC)..~OLA group: olanzapine 10 mg oral each night on days 1-4 after HEC (or days 1-3 after MEC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEX group: Dexamethasone
Description: DEX group: dexamethasone (Decadron) 8 mg oral daily on days 2-4 after HEC (or days 2-3 after MEC)..~OLA group: olanzapine 10 mg oral each night on days 1-4 after HEC (or days 1-3 after MEC).
Study: NCT05693935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-44749 - Dose level 1
Description: In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-44749 - Dose level 2
Description: In Period 1, 2 monthly injections, In Period 2 up to 12 monthly injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-44749 - Dose level 3
Description: In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Period 1, 2 monthly injections (Period 1 only)
Study: NCT04005001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HindSight
Description: HindSight will examine the dynamic trends of clinical measurements taken from a patient's EHR and analyzes correlations between vital signs to alert for the onset of sepsis.This machine learning based tool is optimized by encoder and utilizes periodic retraining to improve its performance over time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: InSight
Description: Compared to the ability of the InSight software's recognition of sepsis onset to HindSight's performance. The study determines if the HindSight software has equivalent or better performance than the InSight software.
Study: NCT04754841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: platelet cryopreservation
Description: The cryopreservation of platelets will be carried out using as alternatives of cryopreservative solution: 5% dimethylsulfoxide alone (solution 1) or combined with 5% dextrose 160 mg (solution 2) or with 2% albumin (solution 3) and then be frozen at -80 ° C
Study: NCT05988580

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pasta dish with resistant starch
Description: Pasta dish with 20-22% of resistant starch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pasta dish with resistant starch
Description: Pasta dish with 20-22% of resistant starch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Original version of pasta dish
Description: Original pasta dish, not reinforced with resistant starch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Original version of pasta dish
Description: Original pasta dish, not reinforced with resistant starch
Study: NCT05581810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: Cognitive behavioural therapy for functional memory symptoms after concussion is delivered by a psychologist over 11 individual (1:1) secure videoconference sessions. The core active ingredients are 1) Behavioural experiments, which acts by phasing out compensatory strategies in order to increase normal memory use and 2) Cognitive reappraisal, which aids in re-interpreting memory lapses in order to reduce reactivity to them.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Rehabilitation
Description: Training and practice with external memory aids/compensatory strategies, adapted from Shum et al. (2011). J Rehabil Med, 43(3):216-223.
Study: NCT04955691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low carbohydrate diet
Description: Participants will engage in a diet that limits carbohydrate intake to 15% of total daily calories for 2 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard carbohydrate diet
Description: Participants will engage in a diet that recommends standard carbohydrate intake with respect to total daily calories for 2 weeks.
Study: NCT06393179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pressure-volume curve with a low-flow insufflation of 5 L/min
Description: The patient undergoes a pressure-volume curve with a low-flow insufflation of 5 L/min while in a state of analgesia, sedation, and absence of spontaneous breathing.
Study: NCT04572451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Nivolumab (BMS-936558-01), 480 mg intravenous (every 4 weeks)~Treatment must be within 7 days of the last dose of radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986253
Description: BMS-986253 (Anti-IL-8), 2,400 mg intravenous (every 2 weeks)~Treatment must be within 7 days of the last dose of radiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: Stereotactic Body Radiotherapy (SBRT) (varying doses)~SBRT: Initial Dose fractionation of 3 or 5 fractions of radiation as determined by the location of the metastases to be irradiated, to at least 1 but no more than 4 metastatic lesions. There will be a minimum of 40 hours between treatments for an individual metastasis.~SBRT must be completed within a 14-day window, separate from the screening phase. Treatment with nivolumab and BMS-986253 must be within 7 days of the last dose of radiation.
Study: NCT05747144

Intervention type: DIAGNOSTIC_TEST
Intervention: Biometry
Description: Biometric measurements performed with IOL Master, if executable Contact or immersion echobiometry if IOL Master cannot be performed
Study: NCT06443229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded Activity based in exercises and educational approach
Description: Exercises for warming up, strengthening, and relaxation, along with informational sessions incorporating an educational approach for low back pain using Telerehabilitation platform. Participants will be randomized into two groups: the Experimental Group (EG), which will receive graded activity along with the educational approach, three times a week, over 12 sessions, totaling 4 weeks.~The intervention will involve adapting a protocol from an exercise program based on gradual activity with progressively increasing exercise intensity using web applications from Physitrack® Ltd., LDN, United Kingdom (used by the physiotherapist/researcher) and Physiapp® (used by the participant). Participants will be provided with (i) a welcome letter outlining the intervention/group components they are allocated to; (ii) instructions on how to use the Physiapp® web application (web browser, Android or iOS app) at home.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Educational Approach
Description: Educational approach for low back pain using Telerehabilitation platform. Participants will receive educational materials with an isolated educational approach, with the delivery of the materials occurring three times a week.
Study: NCT05747144

Intervention type: DIAGNOSTIC_TEST
Intervention: Biometry
Description: Biometric measurements performed with IOL Master, if executable Contact or immersion echobiometry if IOL Master cannot be performed

Intervention type: DIAGNOSTIC_TEST
Intervention: Biometry
Description: Biometric measurements performed with IOL Master, if executable Contact or immersion echobiometry if IOL Master cannot be performed
Study: NCT05122169

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: Skin preparation with povidone-iodine pre-vaginal delivery skin preparation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Skin preparation with chlorhexidine-alcohol pre-vaginal delivery skin preparation.
Study: NCT05959226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: 1. Nutrition intervention: From discharge (7-14 days after surgery) until 6 months after surgery, patients are required to take 400 kcal/day of oral nutrition supplement (ONS) in addition to their normal diet..~2. Exercise: under the guidance of the rehabilitation therapist, the patient gradually recovers Exercise from discharge (7-14 days after the operation) to 6 months after the operation, and should ensure at least 150 minutes of moderate intensity exercise or a combination of equivalent activities per week;

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Intervention
Description: (1) Nutrition intervention: From discharge (7-14 days after surgery) until 6 months after surgery, patients are required to take 400 kcal/day of oral nutrition supplement (ONS) in addition to their normal diet..
Study: NCT04994405

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tourniquet Pressure
Description: The procedural intervention will be inflation of a pneumatic tourniquet to a lower than standard pressure as determined by the patient's SBP in hand and upper extremity surgery. The control will be inflation of a pneumatic tourniquet at a standard pressure of 250 mmHg in hand and upper extremity surgery.~The tourniquet used will be the standard tourniquet used for hand and upper extremity surgery at our institutions - a tourniquet 18 inches in length and 3 inches in width manufactured by Stryker (Kalamazoo, MI) used in conjunction with a protective sleeve matched to the size of the tourniquet cuff which is provided by the manufacturer. Both pieces are supplied in a sterile packaging. No other tourniquets will be used.
Study: NCT06552000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200T System
Description: Exposure/Frequency: 150 kHz Route: Transdermal through patented microarray system to the hemithorax affected with cancer, 2-4 week duration, target 18 hours/day (on average)
Study: NCT05180136

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice bran extract group
Description: Rice bran extract 1,000 mg/day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Placebo 1,000 mg/day for 8 weeks
Study: NCT04943731

Intervention type: DEVICE
Group type: OTHER
Intervention: Provox Life
Description: Phase 1: Like for like transition, Phase 2: Provox Life day/night regimen
Study: NCT05155384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: main topics of pain neuroscience education; neurophysiology of the nervous system, protective mechanism of pain, acute pain formation and chronic pain, factors that increase/reduce pain, central sensitization mechanism, neuroplasticity and treatment strategies in chronic pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation exercises
Description: Relaxation exercises are a training based on deep relaxation techniques and visual imagery. Relaxation exercises will be applied at the end of the training sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognition target exercise
Description: Cognition target exercises are a time-based approach that is not symptom-conditioned (not based on fatigue or pain). It includes functional and dynamic exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor stretching exercises
Description: Pelvic floor stretching exercises; consists of stretching exercises involving the pelvic floor muscles and surrounding group muscles (such as piriformis, hamstring, adductor group muscles and lumbar extensors).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: It will be used with superficial electrodes attached to the suprapubic region of the patients for 20 minutes in each session.
Study: NCT04811937

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computer-aided polypectomy decision support by Artificial Intelligence
Description: The AI system will capture the live video of the procedure and the AI feedbackwill be shown on a second screen installed next to the regular endoscopy screen. Screen A will show the regular endoscopy image and screen B will show the regular endoscopy image together with the areas that might harbor a polyp and the information to help the polypectomy.
Study: NCT05912972

Intervention type: OTHER
Intervention: Patient registry
Description: Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures

Intervention type: OTHER
Intervention: Patient registry
Description: Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures

Intervention type: OTHER
Intervention: Patient registry
Description: Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
Study: NCT05475197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: We planned to perform two different taping applications to evaluate the acute effect of kinesio taping application on the carpal tunnels of individuals with carpal tunnel syndrome.
Study: NCT05959226

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition Intervention
Description: (1) Nutrition intervention: From discharge (7-14 days after surgery) until 6 months after surgery, patients are required to take 400 kcal/day of oral nutrition supplement (ONS) in addition to their normal diet..